An automated pheochromocytoma and paraganglioma lesion segmentation AI-model at whole-body 68Ga- DOTATATE PET/CT.
Fahmida Haque, Jorge A Carrasquillo, Evrim B Turkbey...
https://pubmed.ncbi.nlm.nih.gov/39500789/Actively Recruiting
Led by National Cancer Institute (NCI) · Updated on 2026-10-26
130
Participants Needed
1
Research Sites
156 weeks
Total Duration
Pheochromocytoma and paraganglioma are rare tumors that develop in or near the adrenal gland or neck region. These tumors can be difficult to remove with surgery, especially if they have spread, and current treatments for advanced cases are limited. Researchers are evaluating the safety and tolerability of Lu-177-DOTATATE and its potential to extend the time before the cancer returns in people with inoperable, somatostatin receptor-positive tumors. Participants will receive Lu-177-DOTATATE through an intravenous infusion every 8 weeks for a total of four doses. Alongside the drug, an amino acid solution will be infused to protect the kidneys. After each treatment, participants will have scans including Ga-68-DOTATATE PET, F-18-FDG PET, CT, and MRI to monitor the tumors. Imaging and blood tests will be performed throughout the study to track treatment effects and safety. During the study, participants will undergo regular assessments including physical exams, blood and urine tests, and quality of life questionnaires. Follow-up will occur every 3 to 6 months for up to 3 years or until the disease worsens, with additional yearly contacts thereafter. Researchers will measure progression-free survival at 6 months as the primary outcome along with tumor progression time, overall survival, safety, and changes in biochemical markers and medication use.
CONDITIONS
Lu-177-DOTATATE (Lutathera) in Therapy of Inoperable Pheochromocytoma/ Paraganglioma
J
Joy H Zou, R.N.
F
Frank I Lin, M.D.
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
National Cancer Institute (NCI)
Lead Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | Investigational PRRT (Lu‑177‑DOTATATE) | Current systemic option (I‑131‑MIBG) |
|---|---|---|
| What it is | An investigational peptide receptor radionuclide therapy using intravenous Lu‑177‑DOTATATE administered at weeks 1, 8, 16 and 24, with Ga‑68‑DOTATATE PET/CT imaging in follow‑up as described in the registry | A long‑established systemic therapy using I‑131‑MIBG, FDA‑approved and guideline‑recommended for unresectable or metastatic pheochromocytoma/paraganglioma |
| Role in trial | The only study treatment administered to all participants in this single‑group trial | Not part of the trial, shown here for external clinical context |
| Primary use | To treat inoperable or metastatic SSTR‑positive PPGL with progressive disease | To target norepinephrine transporter‑expressing PPGL lesions in unresectable or metastatic disease |
| How it is administered | Administered intravenously at weeks 1, 8, 16, and 24 with imaging follow‑up over 3 years as per protocol | Given as an intravenous radiopharmaceutical infusion (I‑131‑MIBG), schedule per standard clinical protocol |
| Evidence status | Evidence currently limited to single‑group evaluation; efficacy and safety under investigation | Widely used based on long‑standing clinical experience, though randomized comparative trials are limited |
| Important risks | Safety being evaluated; potential risks include hematologic, renal toxicity and catecholamine crisis during PRRT | Known risks include radiation‑induced cytopenias and thyroid dysfunction following systemic radiotherapy |
| Important limitations | Single‑group design lacks direct comparison; long‑term benefits and outcomes remain unknown | Variable response rates and limited access depending on facility and tracer availability |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - Approximately 24 weeks
Participants receive Lu-177-DOTATATE through intravenous infusions every 8 weeks for a total of 4 doses, along with an amino acid infusion for kidney protection. Imaging scans and lab tests are conducted to monitor response and safety.
Visits every 8 weeks for infusions and assessments
Duration - Up to 3 years or until disease progression
After treatment, participants are followed every 3 to 6 months for up to 3 years to monitor disease status and quality of life. Annual contacts continue thereafter to assess survival and health.
Follow-up visits every 3 to 6 months
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Have more questions? Get in touch with our team for quick support
Fahmida Haque, Jorge A Carrasquillo, Evrim B Turkbey...
https://pubmed.ncbi.nlm.nih.gov/39500789/Sriram Gubbi, Mohammad Al-Jundi, Sungyoung Auh...
https://pubmed.ncbi.nlm.nih.gov/37886645/Sriram Gubbi, Mohammad Al-Jundi, Jaydira Del Rivero...
https://pubmed.ncbi.nlm.nih.gov/33551992/Jacques W M Lenders, Quan-Yang Duh, Graeme Eisenhofer...
https://pubmed.ncbi.nlm.nih.gov/24893135/Seong-Jang Kim, Kyoungjune Pak, Phillip J Koo...
https://pubmed.ncbi.nlm.nih.gov/26253273/J B Maurice, R Troke, Z Win...
https://pubmed.ncbi.nlm.nih.gov/22526961/National Cancer Institute (NCI)
Lead Sponsor